Significant advances in novel therapeutics have been made for patients with relapsed/refractory MCL (R/R MCL) including Bruton’s tyrosine kinase (Btk) inhibitors and cellular therapy with anti-CD19 chimeric antigen receptor (CAR) T-cells [6]. Here, BTK is linked to mantle cell lymphoma.